SmartNuclide Biopharma
Shanghai, China· Est.
A clinical-stage biotech developing targeted alpha-particle and radioligand therapies for solid tumors.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A clinical-stage biotech developing targeted alpha-particle and radioligand therapies for solid tumors.
Oncology
Technology Platform
Platform for developing targeted radionuclide conjugates, focusing on novel targeting vectors and linker chemistry to optimize tumor delivery of alpha- or beta-emitting isotopes.
Opportunities
The global radiopharmaceutical therapeutics market is expanding rapidly, driven by clinical success; there is significant unmet need in oncology and a strategic push in China for domestic nuclear medicine capabilities.
Risk Factors
High clinical development risk, complex manufacturing and supply chain for radioactive isotopes, intense competition from established global pharma, and regulatory hurdles specific to radiopharmaceuticals.
Competitive Landscape
Competes with Novartis (Pluvicto, Lutathera), Bayer (Xofigo), and other biotechs like Fusion Pharmaceuticals and RayzeBio; differentiation hinges on novel targeting, improved safety profiles, and focus on the Chinese market.